Drugs / human retinal progenitor cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02464436 | Dec 2015 → Jun 2022 | retinitis pigmentosa | ReNeuron Limited | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human retinal progenitor cells | “Single subretinal administration of human retinal progenitor cells (hRPC)” NCT02464436 ↗ |
| Known as | hRPC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02464436 ↗ |
| Modality | Cell therapy | “hRPC is a cell therapy for retinitis pigmentosa.” NCT02464436 ↗ |
| Route | Other | “subretinal implantation of hRPC” NCT02464436 ↗ |